<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271517</url>
  </required_header>
  <id_info>
    <org_study_id>Eudract-number 2005-001726-80</org_study_id>
    <nct_id>NCT01271517</nct_id>
  </id_info>
  <brief_title>Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis</brief_title>
  <acronym>BAS</acronym>
  <official_title>Effects of New Longacting Insulin Analogs on Metabolic Control, Endogenous Insulin Production, GH/IGF-I Axis and Quality of Life - Comparison of NPH, Glargine Och Detemir Insulin From the Debut of Type 1 Diabetes Mellitus in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Basal insulin analogs with continuous 24-hour delivery of insulin improve
      glycemic control during the first year of treatment of children/adolescents with type 1
      diabetes mellitus (T1DM)by preserving endogenous insulin production and a close to normal
      balance of the GH-IGF-axis.

      This a randomized, open-label, parallel-group trial of 120 children, 7 - 17 years of age,
      newly diagnosed with T1DM. The investigators will investigate whether the use of long-acting
      basal insulin analogs Lantus (Glargine) or Levemir (Detemir) during the first year of
      treatment results in improved glycemic control (HbA1c) compared with Insulatard (NPH insulin)
      when given in a meal insulin therapy regimen with rapid acting Novorapid (insulin aspart).
      The investigators will explore possible mechanisms of action by determining remaining
      endogenous insulin production and changes in the GH-IGF-axis. The investigators will also
      assess changes in body composition and evaluate quality of life in each treatment arm.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>1 year</time_frame>
    <description>The study compare HbA1c one year after start of treatment at diagnosis of T1DM in patients treated with Lantus or Levemir with patients treated with Insulatard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stimulated C-peptide</measure>
    <time_frame>2 weeks and 3, 6 and 12 month</time_frame>
    <description>Sustacal stimulated C-peptide after an overnight fast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-I</measure>
    <time_frame>diagnosis, 2 weeks, 3,6,9 and 12 month</time_frame>
    <description>Serum IGF-I concentrations</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>Insulatard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugars</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment once daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levemir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin</intervention_name>
    <description>Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar</description>
    <arm_group_label>Insulatard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars</description>
    <arm_group_label>Lantus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir</intervention_name>
    <description>Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars</description>
    <arm_group_label>Levemir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes and novel to insulin therapy

          -  Age 7 - 17 years

          -  Informed consent

        Exclusion Criteria:

          -  Moderate to severe ketoacidosis (pH&lt;7.2 and/or standard bicarbonate &lt;10 mmol/l)

          -  Suspected non-type 1

          -  IA2 and GAD65: all-antibody negative

          -  Celiac disease or other chronic disease

          -  Hypothyroidism, if not well controlled

          -  Syndromes

          -  Previous anorexia nervosa

          -  Neuro-psychiatric disease

          -  Malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Pediatrics, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Peter Bang, MD, PhD, Associated Professor</name_title>
    <organization>Karolinska Institutet</organization>
  </responsible_party>
  <keyword>Basal insulin</keyword>
  <keyword>long acting insulin analogs</keyword>
  <keyword>metabolic control</keyword>
  <keyword>HbA1c</keyword>
  <keyword>C-peptide</keyword>
  <keyword>IGF-I</keyword>
  <keyword>GH</keyword>
  <keyword>IGFBP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

